In addition, Concentra has granted the underwriters a 30-day option to purchase up to an additional 3,375,000 shares of its common stock to cover over-allotments, if any. Concentra's common stock has been approved for listing on the New York Stock Exchange under the symbol "CON" and is expected to begin trading on July 25, 2024. The IPO is expected to close on July 26, 2024, subject to the satisfaction or waiver of customary closing conditions.
After the completion of the IPO, Select Medical will own 104,093,503 shares of Concentra's common stock, representing 82.23% of the total outstanding shares of Concentra's common stock (or 80.09% if the underwriters exercise in full their over-allotment option).